NO994103D0 - Reverse hydroxamate derivatives as metal protease inhibitors - Google Patents

Reverse hydroxamate derivatives as metal protease inhibitors

Info

Publication number
NO994103D0
NO994103D0 NO994103A NO994103A NO994103D0 NO 994103 D0 NO994103 D0 NO 994103D0 NO 994103 A NO994103 A NO 994103A NO 994103 A NO994103 A NO 994103A NO 994103 D0 NO994103 D0 NO 994103D0
Authority
NO
Norway
Prior art keywords
protease inhibitors
metal protease
hydroxamate derivatives
reverse hydroxamate
reverse
Prior art date
Application number
NO994103A
Other languages
Norwegian (no)
Other versions
NO994103L (en
Inventor
Robert Carl Andrews
Dulce Garrido Bubacz
Joseph Howing Chan
Michael David Gaul
Darryl Lynn Mcdougal
David Lee Musso
Michael Howard Rabinowitz
Jennifer Badiang Stanford
Robert William Wiethe
Marc W Andersen
David John Cowan
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO994103D0 publication Critical patent/NO994103D0/en
Publication of NO994103L publication Critical patent/NO994103L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO994103A 1997-02-26 1999-08-25 Reverse hydroxamate derivatives as metal protease inhibitors NO994103L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3911297P 1997-02-26 1997-02-26
PCT/EP1998/001015 WO1998038179A1 (en) 1997-02-26 1998-02-24 Reverse hydroxamate derivatives as metalloprotease inhibitors

Publications (2)

Publication Number Publication Date
NO994103D0 true NO994103D0 (en) 1999-08-25
NO994103L NO994103L (en) 1999-10-25

Family

ID=21903750

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994103A NO994103L (en) 1997-02-26 1999-08-25 Reverse hydroxamate derivatives as metal protease inhibitors

Country Status (16)

Country Link
EP (1) EP1019386A1 (en)
JP (1) JP2001513767A (en)
KR (1) KR20000075681A (en)
AP (1) AP9901631A0 (en)
AR (1) AR013070A1 (en)
AU (1) AU6822398A (en)
BR (1) BR9807763A (en)
CA (1) CA2281664A1 (en)
HR (1) HRP980096A2 (en)
IS (1) IS5159A (en)
NO (1) NO994103L (en)
PE (1) PE59199A1 (en)
PL (1) PL335378A1 (en)
TR (1) TR199902063T2 (en)
WO (1) WO1998038179A1 (en)
ZA (1) ZA981532B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235786B1 (en) 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
US6294573B1 (en) 1997-08-06 2001-09-25 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
DE69917221T2 (en) 1998-02-07 2005-05-04 Vernalis (Oxford) Ltd., Abington ANTIBACTERIAL AGENTS
WO2000012466A1 (en) * 1998-08-26 2000-03-09 Glaxo Group Limited Formamide compounds as therapeutic agents
GB9818621D0 (en) * 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therapeutic agents
WO2000012083A1 (en) * 1998-08-26 2000-03-09 Glaxo Group Limited Formamides as therapeutic agents
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
GB9918869D0 (en) * 1999-08-10 1999-10-13 British Biotech Pharm Antibacterial agents
JP2003081838A (en) * 2001-09-11 2003-03-19 Rohto Pharmaceut Co Ltd Glucosamine preparation
US7011854B2 (en) 2002-02-04 2006-03-14 Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO, compounds having the ability to release CO and pharmaceutical compositions thereof
WO2004071384A2 (en) * 2003-02-11 2004-08-26 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and tace-inhibitors
US20070203244A1 (en) * 2006-02-09 2007-08-30 Strongin Alex Y Inhibitors of membrane type-1 matrix metalloproteinase for the treatment of insulin-dependent diabetes mellitus
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EA022505B1 (en) 2008-03-25 2016-01-29 Эффектис Фармасьютиклз Аг Novel p2x7r antagonists and their use
PT2243772E (en) 2009-04-14 2012-03-28 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
JP6134710B2 (en) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． Ruthenium monoxide releasing molecules and uses thereof
BR112021006407A8 (en) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med use of egfr inhibitors for keratoderms

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
CN1049651C (en) * 1994-01-20 2000-02-23 英国生物技术药物有限公司 Metalloproteinase inhibitors
GB9514867D0 (en) * 1995-07-20 1995-09-20 British Biotech Pharm Metalloproteinase inhibitors
WO1997019053A1 (en) * 1995-11-23 1997-05-29 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors

Also Published As

Publication number Publication date
PE59199A1 (en) 1999-06-24
CA2281664A1 (en) 1998-09-03
EP1019386A1 (en) 2000-07-19
JP2001513767A (en) 2001-09-04
WO1998038179A1 (en) 1998-09-03
PL335378A1 (en) 2000-04-25
BR9807763A (en) 2000-02-22
TR199902063T2 (en) 1999-12-21
HRP980096A2 (en) 1998-12-31
IS5159A (en) 1999-08-20
AR013070A1 (en) 2000-12-13
AP9901631A0 (en) 1999-09-30
NO994103L (en) 1999-10-25
KR20000075681A (en) 2000-12-26
ZA981532B (en) 1999-08-24
AU6822398A (en) 1998-09-18

Similar Documents

Publication Publication Date Title
NO994103D0 (en) Reverse hydroxamate derivatives as metal protease inhibitors
NO995433D0 (en) Protease inhibitors
NO20012980D0 (en) protease inhibitors
ATE259352T1 (en) CYSTEINE PROTEASE INHIBITORS
EE04466B1 (en) Sulphonamide derivatives as aspartyl protease inhibitors
NO992821D0 (en) Ketobenzamides as Calpain Inhibitors
DK2253620T3 (en) SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN-TYROSINKINASE INHIBITORS
NO20002826L (en) Hydroxamic Acid Derivatives as Matrix Metal Protease (MMP) Inhibitors
NO991922D0 (en) Heteroarlsuccinamides and their use as metalloproteinase inhibitors
NO975742D0 (en) Reversible cysteine protease inhibitors
NO992492D0 (en) Benzamidoaldehydes and their use as cysteine protease inhibitors
NO990759D0 (en) Heterocyclic Metal Protease Inhibitors
NO992725L (en) 6-Phenylpyridyl-2-amine derivatives useful as NOS inhibitors
ATE264339T1 (en) SERINE PROTEASE INHIBITORS
DK1027332T3 (en) New lactametalloprotease inhibitors
NO20005196L (en) Substituted pyrrolidine hydroxamate metal protease inhibitors
NO20004696L (en) Quinolones as Serine Protease Inhibitors
ATE325091T1 (en) ASPARTYL PROTEASE INHIBITORS
NO974403D0 (en) Reversible protease inhibitors
NO995434D0 (en) protease inhibitors
NO995435D0 (en) Protease inhibitors
NO20003256D0 (en) ACE inhibitor-MMP inhibitor combinations
NO995268D0 (en) protease inhibitors
DK1023268T3 (en) Isoquinolines as urokinase inhibitors.
NO20002938L (en) Fibrinolytic inhibitor as a sealant